Merck & Co., Inc. (NYSE:MRK) is scheduled to release its earnings data before the market opens on Thursday, July 29th. Analysts expect Merck & Co., Inc. to post earnings of $1.58 per share for the quarter. Persons that are interested in registering for the company's earnings conference call can do so using this link.
Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Thursday, April 29th. The company reported $1.40 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $1.63 by ($0.23). Merck & Co., Inc. had a return on equity of 54.15% and a net margin of 14.64%. The firm had revenue of $12.08 billion for the quarter, compared to the consensus estimate of $12.71 billion. During the same period last year, the company posted $1.50 earnings per share. The business's revenue was up .2% compared to the same quarter last year. On average, analysts expect Merck & Co., Inc. to post $6 EPS for the current fiscal year and $6 EPS for the next fiscal year.
NYSE MRK opened at $76.39 on Thursday. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.02 and a quick ratio of 0.78. The stock's fifty day moving average price is $76.97. Merck & Co., Inc. has a 1 year low of $71.71 and a 1 year high of $87.80. The company has a market capitalization of $193.42 billion, a price-to-earnings ratio of 27.68, a P/E/G ratio of 2.24 and a beta of 0.41.
The business also recently disclosed a dividend, which was paid on Wednesday, June 2nd. Shareholders of record on Friday, June 4th were issued a $0.65 dividend. The ex-dividend date of this dividend was Thursday, June 3rd. This represents a dividend yield of 3.42%. Merck & Co., Inc.'s dividend payout ratio is currently 43.77%.
Several research firms have commented on MRK. Argus reiterated a "hold" rating on shares of Merck & Co., Inc. in a report on Thursday, May 20th. Truist Securities decreased their price objective on shares of Merck & Co., Inc. from $96.00 to $93.00 and set a "buy" rating on the stock in a report on Monday, June 7th. JPMorgan Chase & Co. decreased their price objective on shares of Merck & Co., Inc. from $105.00 to $100.00 and set an "overweight" rating on the stock in a report on Wednesday, June 9th. Finally, SVB Leerink decreased their price objective on shares of Merck & Co., Inc. from $102.00 to $99.00 and set an "outperform" rating on the stock in a report on Thursday, June 3rd. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. The stock presently has an average rating of "Buy" and a consensus target price of $97.00.
In related news, EVP Frank Clyburn sold 19,324 shares of the company's stock in a transaction dated Monday, May 10th. The shares were sold at an average price of $78.32, for a total value of $1,513,455.68. Corporate insiders own 0.32% of the company's stock.
An institutional investor recently bought a new position in Merck & Co., Inc. stock. OLD Mission Capital LLC acquired a new position in shares of Merck & Co., Inc. (NYSE:MRK) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 2,980 shares of the company's stock, valued at approximately $247,000. Hedge funds and other institutional investors own 71.71% of the company's stock.
Merck & Co., Inc. Company Profile
Merck & Co, Inc engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
Read More: How is the LIBOR rate calculated?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider Merck & Co., Inc., you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck & Co., Inc. wasn't on the list.
While Merck & Co., Inc. currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The 5 Stocks Here